A Phase 1 interventional study of ENX-104 and Placebo in Major Depressive Disorder, sponsored by Engrail Therapeutics INC. Completed at 4 sites in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by Engrail Therapeutics INC · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Depressive Disorder, Major with a site in United Kingdom — 17 open to participants now, 19 under way, 7 of them phase 3. Depressive Disorder, Major · United Kingdom.
Among the 96 studies in Depressive Disorder, Major with a site in United Kingdom, this one is the 67th largest by enrollment of the 84 interventional ones that give a count, is one of 8 that started in 2025, is one of 11 in phase 1, and was the 86th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →17 of the 96 studies in Depressive Disorder, Major with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Oxford · Sites in United Kingdom
Ages 18–65
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 18–75
Eli Lilly and Company · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 18–75
Draig Therapeutics Ltd · Sites in United Kingdom, United States, Bulgaria and 2 more countries
Ages 18–75
Cybin IRL Limited · Sites in United Kingdom, United States, Australia and 5 more countries
Ages 18–85
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 21 · Phase 3 23 · Phase 4 4
First in 2004; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 141 across the 84 interventional studies, 46 across the 12 observational. Of the 67 that completed or were terminated, 29 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 96 have an industry lead sponsor. The 10 most frequent:
Engrail Therapeutics INC is the lead sponsor of 8 studies on the registry; none are open to participants now.
Engrail Therapeutics INC has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
8 of the studies in Depressive Disorder, Major with a site in United Kingdom that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06793397Phase 3Cybin IRL LimitedA Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | 2027-06-07 |
| NCT06963021Phase 3Neurocrine BiosciencesNBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | 2027-07 |
| NCT06470035Neurovalens Ltd.Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Major Depressive Disorder (MDD) | 2027-04 |
| NCT07228468King's College LondonHome-Based Transcranial Direct Current Stimulation In Major Depressive Disorder (HOME) | 2027-05-15 |
| NCT07879924Mersey Care NHS TrustDual Neuromodulation for Depression: Boosting TMS With tES | 2027-08 |
Add all 8 to your calendar (.ics) → With an account.
Among the 96 studies in Depressive Disorder, Major with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ENX-104 in participants with major depressive disorder with anhedonia (aMDD).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Biologically female participants (defined as assigned female at birth)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ENX-104
Drug: Placebo
Oral Solution
Oral solution
Number of Participants with Treatment Emergent Adverse Events (TEAE)
Time frame: From Day 1 up to Day 21
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2025 to primary completion in Nov 2025, 9 months.
Of 40 industry-sponsored phase 1 interventional studies under Depressive Disorder, Major, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 12. This study's 9 months is above that.
Counting every sponsor, half of 88 studies reached it within 16 months; a quarter within 5 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ENX-104
Engrail Therapeutics INC